Chao Liu1, Jingjing Piao2, Zhiyang Shang3. 1. Department of Oncology, Zhuozhou Hospital, No.129, Fanyang Road, Zhuozhou City, Hebei Province, China. 2. College of Nursing, Hebei University of Chinese Medicine, Shijiazhuang, Hebei Province, China. 3. Department of Oncology, Zhuozhou Hospital, No.129, Fanyang Road, Zhuozhou City, Hebei Province, China. shangzhiyang85@163.com.
Abstract
BACKGROUND: Studies have shown that immune checkpoint inhibitors (ICIs) have limited efficacy and can even increase tumour burden in short time periods. This is usually called hyperprogressive disease (HPD). To date, there are few reports regarding HPD; fewer have analysed the relationship between HPD and radiotherapy combined with ICIs, and their conclusions are controversial. CASE PRESENTATION: A 42-year-old woman was diagnosed with stage IV renal clear cell carcinoma. The patient had previously received sorafenib and pazopanib as first- and second-line therapies, respectively. She received radiotherapy combined with nivolumab. Eighteen days after administration of the third dose of nivolumab, the patient's general condition deteriorated; this was associated with immune-related adverse events. Computed tomography showed that the diameter of left lung metastases had sharply increased. A biopsy of the lung metastasis showed no infiltration of lymphocytes. The patient's general condition worsened and she died of the disease on the 70th day after administration of the third dose of nivolumab. CONCLUSIONS: This report describes the development of HPD following the administration of radiotherapy combined with ICIs in a case of advanced renal cell carcinoma. The case indicates that radiotherapy may show bidirectional regulation effects on anti-tumour immune response. If the immunosuppressive function of radiotherapy is dominant, combined with ICIs, it could result in HPD.
BACKGROUND: Studies have shown that immune checkpoint inhibitors (ICIs) have limited efficacy and can even increase tumour burden in short time periods. This is usually called hyperprogressive disease (HPD). To date, there are few reports regarding HPD; fewer have analysed the relationship between HPD and radiotherapy combined with ICIs, and their conclusions are controversial. CASE PRESENTATION: A 42-year-old woman was diagnosed with stage IV renal clear cell carcinoma. The patient had previously received sorafenib and pazopanib as first- and second-line therapies, respectively. She received radiotherapy combined with nivolumab. Eighteen days after administration of the third dose of nivolumab, the patient's general condition deteriorated; this was associated with immune-related adverse events. Computed tomography showed that the diameter of left lung metastases had sharply increased. A biopsy of the lung metastasis showed no infiltration of lymphocytes. The patient's general condition worsened and she died of the disease on the 70th day after administration of the third dose of nivolumab. CONCLUSIONS: This report describes the development of HPD following the administration of radiotherapy combined with ICIs in a case of advanced renal cell carcinoma. The case indicates that radiotherapy may show bidirectional regulation effects on anti-tumour immune response. If the immunosuppressive function of radiotherapy is dominant, combined with ICIs, it could result in HPD.
Authors: Encouse B Golden; Sandra Demaria; Peter B Schiff; Abraham Chachoua; Silvia C Formenti Journal: Cancer Immunol Res Date: 2013-12 Impact factor: 11.151
Authors: Kristian M Koller; Heath B Mackley; Jason Liu; Henry Wagner; Giampaolo Talamo; Todd D Schell; Colette Pameijer; Rogerio I Neves; Bryan Anderson; Kathleen M Kokolus; Carol A Mallon; Joseph J Drabick Journal: Cancer Biol Ther Date: 2016-12-01 Impact factor: 4.742
Authors: Chad Tang; Zhongxing Liao; Daniel Gomez; Lawrence Levy; Yan Zhuang; Rediet A Gebremichael; David S Hong; Ritsuko Komaki; James W Welsh Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-08 Impact factor: 7.038